S&P Futures
6,008.25 +1.75 (+0.03%) Dow Futures
44,837.00 +11.00 (+0.02%) Nasdaq Futures
20,899.50 +19.25 (+0.09%) Russell 2000 Futures
2,441.90 -9.10 (-0.37%) Crude Oil
69.17 +0.23 (+0.33%) Gold
2,624.40 +5.90 (+0.23%)
Renovaro Inc. (RENB)
After hours:
| Previous Close | 0.5190 |
| Open | 0.5034 |
| Bid | 0.4840 x 100 |
| Ask | 0.5271 x 100 |
| Day's Range | 0.5000 - 0.5535 |
| 52 Week Range | 0.3950 - 5.2500 |
| Volume | |
| Avg. Volume | 476,025 |
| Market Cap | 82.374M |
| Beta (5Y Monthly) | 0.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9400 |
| Earnings Date | Feb 12, 2025 - Feb 17, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRenovaro Issues Shareholder Letter and Provides Corporate Update
LOS ANGELES, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a pioneer in cancer diagnostics and therapeutics powered by artificial intelligence, today issued a letter to shareholders from Chief Executive Officer David Weinstein. Dear Shareholders, It is my honor to address you as the newly appointed CEO of Renovaro Inc. After careful consideration, I left a 40-year career on Wall Street to join Renovaro because I believe the Company has tremendous potential in its verticals, suc
GlobeNewswireRenovaroCube Presents Novel Insights on Non-Invasive Cancer Diagnostics Using Oxford Nanopore Sequencing
AMSTERDAM, Oct. 17, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) – RenovaroCube, a leader in AI-driven cancer diagnostics by integrating multi-omics with liquid biopsies, is excited to announce the presentation of its latest research at the Molecular Analysis for Precision Oncology Congress – on October 16, 2024. This study investigates the use of Oxford Nanopore sequencing on circulating cell-free DNA (cfDNA) derived from blood plasma to detect key copy number alterations (CNAs) in lung cancer patie
